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Abstract
Objective: Hyperhomocysteinemia and increased inflammatory cytokines 
are independent risk factors in patients with renal diseases. N-acetylcysteine 
(NAC) is an antioxidant that is known to decrease inflammatory cytokines 
and plasma total homocysteine (tHcy). Therefore, the aim of this study was 
to compare normal saline injection with and without intravenous NAC 
during hemodialysis (HD) in terms of changes in serum levels of tumor 
necrosis factor-α (TNF-α), interleukin-10 (IL-10), high-sensitivity C-reactive 
protein (hs-CRP) and plasma tHcy.
Patients and Methods: In total, 43 high flux HD patients were enrolled at 
a 4-hour HD session and split into two groups, NAC (n = 22) and NS (n = 21) 
treatment groups, which received either a normal saline injection with 
intravenous NAC or without intravenous NAC, respectively. The NS group 
was divided into two subgroups, one with residual renal function (n = 5) 
and the other with anuria (n = 16). The NAC group was also divided into two 
subgroups, one with residual renal function (n = 6) and the other with anu-
ria (n = 16). Serum TNF-α, IL-10, hs-CRP and tHcy were measured before 
and immediately after HD.
Results: There were no significant differences in baseline characteristics, 
TNF-α, IL-10, hs-CRP, and tHcy levels in intra- and intergroup comparisons. 
Compared to pre-HD baseline values, plasma tHcy level was lower after 
HD in the NS group (p < 0.001), NS with anuria subgroup (p = 0.001), NS with 
residual renal function subgroup (p = 0.034), NAC group (p < 0.001), NAC 
with residual renal function subgroup (p < 0.001), and NAC with anuria 
subgroup (p = 0.003). There were no statistically significant differences in 
plasma tHcy level when the NS group was compared with the NAC group. 
Plasma tHcy level was significantly lower in the NAC with residual renal 
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1. Introduction
Cardiovascular disease (CVD) represents the leading 
cause of death in hemodialysis (HD) patients [1,2]. 
The increased incidence of CVD in dialysis patients 
can only be partially explained by an increased preva-
lence of traditional risk factors, such as hypertension, 
diabetes mellitus, dyslipidemia, smoking, obesity, and 
physical inactivity. Additional risk may result from non-
traditional factors that are frequently observed in ure-
mic patients, such as hyperhomocysteinemia and 
inflammation [3,4].
It has been noted that uremic patients are charac-
terized by a state of chronic inflammation [2]. A wide 
array of inflammatory biomarkers, such as high sen-
sitivity C-reactive protein (hs-CRP), tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-10 
(IL-10), are associated with uremic patients [5–7]. The 
combination of an impaired immune response cou-
pled with persistent immune stimulation may play a 
role in the low-grade systemic inflammation and al-
tered cytokine balance that characterizes the uremic 
state; this may represent an increased CVD risk [5].
N-acetylcysteine (NAC) is an antioxidant and cyto-
protective agent with a scavenging action against reac-
tive oxygen species that also inhibits inflammatory 
cytokines such as TNF-α and IL-10 [8,9]. Intravenous 
administration of NAC can reduce the plasma total 
homocysteine (tHcy) level in healthy individuals [10] 
or in patients undergoing cardiac angiography [11]. 
Intravenous administration of NAC during HD can also 
normalize plasma homocysteine concentration, which 
is associated with an improved pulse pressure in ure-
mic patients [12,13]. Therefore, the aim of this pro-
spective, double-blinded, randomized study was to 
compare normal saline injections with or without in-
travenous NAC in terms of changes in inflammatory 
cytokines (TNF-α, IL-10), hs-CRP and plasma tHcy levels 
in HD patients before and after a 4-hour HD session.
2. Patients and methods
2.1. Patients
Forty-three HD patients were using the same high flux 
polysulfone disposable artificial kidney (FX Class 
Dialyzer; Fresenius Medical Care, Bad Homburg, 
Germany). They consisted of 28 men and 15 women, 
who had a daily oral intake of 5 mg folic acid together 
with B vitamins complex (25 mg B1, 25 mg B6, and 
0.25 mg B12). They were examined during April 2007 
at a medical center in Hualien in eastern Taiwan. Pa-
tients from our HD program were invited to partici-
pate in the study if they were > 18 years of age, were 
receiving standard 4-hour dialysis three times a week 
using standard bicarbonate dialysate, and had been 
on dialysis for at least 3 months. Patients were excluded 
if they had a life expectancy < 3 months, malignancy, 
active infection, a known allergy to NAC or refused/
unable to provide informed consent. The Protection 
of Human Subjects Institutional Review Board at Tzu 
Chi University and Hospital approved the study. Kt/V 
was measured according to Daugirdas’ formula before 
dialysis and immediately after dialysis using a formal 
single-compartment dialysis urea kinetic model.
2.2. Study protocol
Patients were randomly divided into two groups. 
Patients in the NAC and NS groups received intrave-
nous normal saline with or without NAC, respectively 
(5 g, 25 mL; Hidonac, Zambon Group SPA, Milan, Italy) 
function subgroup compared with the NS group (p = 0.002), the NAC with 
residual renal function subgroup compared with the NS with anuria sub-
group (p < 0.001), and the NAC with residual renal function subgroup com-
pared with the NAC with anuria subgroup (p  = 0.001). Moreover, the 
reduction in plasma tHcy level during HD was greater in the NAC with resid-
ual renal function subgroup than in the NAC with anuria subgroup 
(p = 0.001).
Conclusion: A normal saline injection is able to decrease plasma tHcy 
during high flux HD with or without NAC. However, a combination of the 
two further decreases plasma tHcy in high flux HD patients who still have 
residual renal function. NAC is only effective when there is residual renal 
function present to decrease plasma tHcy in high flux HD patients. 
[Tzu Chi Med J 2010;22(2):90–95]
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to a total volume of 250 mL during the 4-hour HD 
session. The NS group was divided into two subgroups 
according to the daily urine amount. One was the NS 
with anuria group (16 patients; urine amount < 50 mL/
day) and the other was the NS with residual renal 
function group (5 patients; urine amount ≥ 50 mL/day). 
The NAC group was also divided into two subgroups 
according to the daily urine amount. One was the NAC 
with anuria group (16 patients; urine amount < 50 mL/
day) and the other was the NAC with residual renal 
function group (6 patients; urine amount ≥ 50 mL/day).
2.3. Biochemical investigations
Blood samples were taken from each subject before 
and at 4 hours after HD. Blood samples of approxi-
mately 0.5 mL for measuring the blood cell count 
(Sysmex K-1000; Sysmex America Inc., Mundelein, IL, 
USA) and other data were immediately centrifuged at 
3000 g for 10 minutes. The blood was decanted and 
separated into two parts. One part was stored at 4°C 
for biochemical examination within 1 hour of collec-
tion by an autoanalyzer (COBAS Integra 800; Roche 
Diagnostics, Basel, Switzerland). Plasma tHcy was 
measured by fluorescence polarized light immunoassay 
after reduction of the oxidized and protein-bound 
homocysteine to free homocysteine, and subsequent 
enzymatic conversion to S-adenosyl-L-homocysteine 
(Abbott IMx; Abbott Diagnostics, Chicago, IL, USA). 
The second part was stored at –80°C for later analysis 
of TNF-α and IL-10 concentrations [11,14].
2.4. TNF-a and IL-10 measured by ELISA
TNF-α and IL-10 concentrations in the blood samples 
were separately measured by two antibody enzyme-
linked immunosorbent assays (ELISAs) using a com-
mercial antibody pair, a recombinant standard, and a 
biotin-streptavidin-peroxidase detection system (Pierce-
Endogen, Thermo Fisher Scientific Inc., Rockford, IL, 
USA) as described previously [11,14]. Blood samples 
were collected in serum-separated tubes. All reagents, 
samples, and working standards were brought to 
room temperature and prepared according to the 
manufacturer’s instructions. The optical density was 
determined with an automated ELISA reader at wave-
lengths of 450 nm and 540 nm.
2.5. Statistical analysis
Data are expressed as mean ± standard deviation and 
were tested for normal distribution by Kolmogorov-
Smirnov statistics. Categorical variables were ana-
lyzed by the χ2 test. Comparisons between patients 
were performed using the Student’s independent t 
test (two-tailed) for normally distributed data or the 
Mann-Whitney U test for parameters that presented 
with non-normal distribution (TNF-α, IL-10, hs-CRP, 
tHcy). Data were analyzed using SPSS version 13.0 
(SPSS Inc., Chicago, IL, USA) for Windows. A p value of 
less than 0.05 was considered statistically significant.
3. Results
The clinical characteristics of the HD patients are 
presented in Table 1. The 43 enrolled patients were 
randomly assigned to the NAC or NS group in a 1:1 
ratio. The NAC group consisted of 22 patients and the 
NS group had 21 patients. The NS with anuria sub-
group had 16 patients and the NS with residual renal 
function subgroup had 5 patients. The NAC with anuria 
subgroup had 16 patients and the NAC with residual renal 
function subgroup had 6 patients. There were no intra- 
and intergroup statistical differences in sex distribu-
tion, diabetes, hypertension or biochemical data.
A comparison of laboratory characteristics of in-
flammation and tHcy levels during HD among the 
different groups is presented in Table 2. There were 
no statistically significant differences in serum hs-CRP, 
TNF-α, IL-10, and tHcy levels in terms of intragroup 
and intergroup comparisons. Compared to pre-HD 
baseline values, tHcy level was lower after high flux 
HD in the NS group (p < 0.001), the NS with anuria 
subgroup (p = 0.001), the NS with residual renal func-
tion subgroup (p = 0.034), the NAC group (p < 0.001), 
the NAC with residual renal function subgroup (p < 
0.001), and the NAC with anuria subgroup (p = 0.003). 
Plasma tHcy level was significantly lower in the NAC 
with residual renal function subgroup compared with 
the NS group (p = 0.002), the NAC with residual renal 
function subgroup compared with the NS with anuria 
subgroup (p < 0.001), and the NAC with residual renal 
function subgroup compared with the NAC with anuria 
subgroup (p = 0.001). Moreover, the reduction in plasma 
tHcy level during HD was greater in the NAC with re-
sidual renal function subgroup than in the NAC with 
anuria subgroup (p = 0.001).
4. Discussion
The results of our study reveal that a normal saline 
injection, with or without intravenous NAC, can de-
crease plasma tHcy after a 4-hour high flux HD session 
in HD patients. There were no statistically significant 
differences in plasma tHcy between a normal saline 
injection with or without intravenous NAC. However, 
the combination of the two further decreases plasma 
tHcy in high flux HD patients who still have residual 
renal function.
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Inflammation frequently accompanies uremia in 
patients because of decreased renal clearance of in-
flammatory cytokines, comorbid conditions such as 
diabetes and inflammatory kidney disease, and other 
dialysis-related factors [4]. HD-induced inflammation 
has been linked to the development of long-term 
morbidity and an increased risk of cardiovascular 
mortality in uremic patients [15,16]. CVD is the single 
largest cause of morbidity and mortality in this popula-
tion [1,2]. Studied inflammatory markers, including 
hs-CRP, TNF-α, IL-6 and IL-10, are associated with ure-
mic patients [5–7]. IL-10 appears to play a critical role 
in suppressing the inflammatory response, and IL-6 
and TNF-α seem to have proinflammatory and proath-
erogenic properties [6]. NAC inhibits phagocyte oxida-
tive responses induced by advanced oxidation protein 
products and reduces oxidative stress-related inflam-
mation in HD patients [17]. However, our study did not 
find statistically significant differences in serum hs-
CRP, TNF-α and IL-10 levels after a 4-hour HD session 
when normal saline injections with or without intra-
venous NAC were compared.
Treatment with folic acid, vitamin B12, vitamin B6, 
or a combination can result in a significant decrease 
in plasma tHcy [18]. Hyperhomocysteinemia is con-
sidered to be an independent cardiovascular risk 
factor in uremic patients [18–20], although the most 
recent intervention studies utilizing folic acid and B 
vitamins did not support this hypothesis [21]. The 
accumulation of homocysteine in blood leads to an 
intracellular increase of S-adenosylhomocysteine, a 
powerful competitive methyltransferase inhibitor, which 
is considered to be a predictor of cardiovascular events 
[22]. Intravenous administration of NAC during an 
HD session can normalize plasma tHcy concentration, 
which is associated with an improved pulse pressure 
in HD patients [12,13]. However, chronic oral NAC 
therapy did not significantly reduce tHcy levels in HD 
patients [23]. Our results also showed that plasma 
tHcy was decreased after an intravenous NAC injection 
during the high flux HD session. However, compared 
with a normal saline injection, there were no signifi-
cant differences in the decrease in plasma tHcy levels 
between the two groups. Intravenous NAC adminis-
tration can reduce plasma tHcy by increasing the ex-
cretion of urinary thiols and urinary homocysteine and 
cysteine in the disulfide form [10,24]. Our results 
also showed that intravenous NAC administration in 
Table 1 — Baseline characteristics of hemodialysis patients treated with normal saline (NS) with or without intrave-
nous N-acetylcysteine (NAC) during hemodialysis*†‡
 
NS group NS with anuria
 NS with residual 
NAC group NAC with anuria
 NAC with residual
 
(n = 21) group (n = 16)
 renal function 
(n = 22) group (n = 16)
 renal function
   group (n = 5)   group (n = 6)
Sex (male) 15 (71.4) 11 (68.8) 4 (80.0) 13 (59.1) 10 (62.5) 3 (50.0)
Diabetes (yes) 5 (23.8) 4 (25.0) 1 (20.0) 5 (22.7) 4 (25.0) 1 (16.7)
HT (yes) 11 (52.4) 8 (50.0) 3 (60.0) 12 (54.6) 9 (56.3) 3 (50.0)
Age (yr) 55.05 ± 14.87 56.81 ± 11.92 49.40 ± 22.81 56.45 ± 15.67 58.44 ± 16.25 51.17 ± 13.91
Duration of HD (mo) 64.14 ± 34.38 67.44 ± 33.86 53.60 ± 37.77 49.05 ± 30.54 51.75 ± 35.48 41.83 ± 7.49
Pre-HD body 69.27 ± 14.05 71.24 ± 14.75 62.98 ± 10.29 70.58 ± 15.24 69.90 ± 14.68 72.28 ± 17.23
weight (kg)
Post-HD body 66.28 ± 13.06 68.08 ± 13.65 60.56 ± 10.04 67.81 ± 14.98 67.18 ± 14.55 69.40 ± 17.36
weight (kg)
WBC (×1000/μL) 6.82 ± 2.00 6.56 ± 1.42 7.68 ± 3.36 6.46 ± 1.86 6.75 ± 1.73 5.75 ± 2.16
Hb (g/dL) 10.43 ± 0.84 10.32 ± 0.88 10.78 ± 0.64 9.99 ± 0.99 10.03 ± 1.11 9.88 ± 0.69
Platelets (×1000/μL) 216.05 ± 62.49 221.19 ± 62.56 199.60 ± 66.37 202.81 ± 61.63 201.93 ± 59.32 205.00 ± 29.81
Albumin (g/dL) 4.02 ± 0.36 3.98 ± 0.39 4.16 ± 0.18 4.11 ± 0.74 3.97 ± 0.24 4.48 ± 1.34
AST (IU/L) 20.19 ± 11.11 21.69 ± 12.10 15.40 ± 5.51 16.29 ± 5.52 17.00 ± 5.64 14.50 ± 5.24
ALT (IU/L) 18.33 ± 9.37 19.75 ± 10.08 13.80 ± 5.02 15.86 ± 5.55 15.40 ± 4.85 17.00 ± 7.43
Total cholesterol 161.62 ± 30.38 158.06 ± 27.81 173.00 ± 38.78 158.29 ± 41.16 160.40 ± 39.90 153.00 ± 47.66
(mg/dL)
Triglyceride (mg/dL) 177.48 ± 92.69 177.13 ± 95.43 178.60 ± 93.73 161.43 ± 104.27 163.60 ± 103.70 156.00 ± 115.47
BUN (mg/dL) 67.43 ± 17.65 68.81 ± 18.22 63.00 ± 16.78 67.19 ± 18.47 68.47 ± 20.33 64.00 ± 13.81
Creatinine (mg/dL) 12.00 ± 2.75 11.96 ± 2.72 12.14 ± 3.19 11.37 ± 1.85 12.00 ± 2.75 11.83 ± 1.05
Kt/V (Daugirdas) 1.56 ± 0.28 1.55 ± 0.30 1.60 ± 0.20 1.42 ± 0.26 1.45 ± 0.21 1.36 ± 0.37
*Data presented as n (%) or mean ± standard deviation; †data expressed as n (%) were analyzed by χ2 test and data expressed as mean ± stand-
ard deviation were analyzed by Student’s t test or Mann-Whitney U test; ‡there were no statistically significant differences between groups. 
HT = hypertension; HD = hemodialysis; WBC = white blood cells; Hb = hemoglobin; AST = aspartate aminotransferase; ALT = alanine aminotrans-
ferase; BUN = blood urea nitrogen; Kt/V = fractional clearance index for urea.
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HD patients who have residual renal function further 
reduced plasma tHcy compared with in anuric HD 
patients or in those who were given a normal saline 
injection during a 4-hour high flux HD session. It was 
also found that normal saline infusion reduces plasma 
tHcy during a high flux HD session. This may be due to 
the fact that high flux dialysis itself can lower plasma 
tHcy in HD patients [25]. Further studies are needed 
to clarify the effect on plasma tHcy of normal saline 
infusion during high flux HD or low flux HD sessions.
There were some limitations to our study. First, 
the sample size was small; therefore, a larger study 
is needed to confirm our findings. Second, this study 
employed a cross-sectional design with only a 4-hour 
high flux HD session follow-up. Third, the urinary con-
centration of tHcy was not measured in this study; 
such a measurement would confirm that intravenous 
NAC administration in HD patients who have residual 
renal function is able to further reduce plasma tHcy 
by increasing the excretion of urinary homocysteine 
in the disulfide form. Further studies are needed 
to confirm the association of NAC and plasma tHcy 
level in HD patients.
A normal saline injection with or without intrave-
nous NAC during a 4-hour high flux HD session can 
decrease plasma tHcy in HD patients. However, there 
were no significant differences in the decreases in 
plasma tHcy levels between an intravenous NAC injec-
tion and a normal saline injection after high flux HD. 
Intravenous NAC administration in HD patients who 
have residual renal function was able to further reduce 
plasma tHcy compared with in anuric HD patients 
and those who were given a normal saline injection 
in a 4-hour high flux HD session.
Acknowledgments
This work was supported by a grant (TCRD 95-03) from 
Tzu Chi Hospital.
References
1. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey 
PS. Congestive heart failure in dialysis patients: preva-
lence, incidence, prognosis and risk factors. Kidney Int 
1995;47:884–90.
2. Stenvinkel P, Alvestrand P. Inflammation in end-stage renal 
disease: sources, consequences and therapy. Semin Dial 
2002;15:330–8.
3. Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick 
TH. Does renal failure cause an atherosclerotic milieu in 
Table 2 — Serum TNF-a, IL-10, hs-CRP, and tHcy levels in hemodialysis patients treated with normal saline (NS) with 
or without intravenous N-acetylcysteine (NAC) during hemodialysis*
 
NS group NS with anuria
 NS with residual 
NAC group NAC with anuria
 NAC with residual
 
(n = 21) group (n = 16)
 renal function 
(n = 22) group (n = 16)
 renal function
   group (n = 5)   group (n = 6)
TNF-α (pg/mL)
 Pre-HD 104.05 ± 189.40 69.63 ± 122.01 224.51 ± 337.49 83.21 ± 150.16 98.20 ± 176.52 48.23 ± 50.72
 Post-HD 97.77 ± 199.16 62.33 ± 123.24 230.68 ± 370.51 77.21 ± 156.61 94.73 ± 184.17 34.66 ± 47.93
 Difference 0.80 ± 22.66 –2.66 ± 20.19 6.17 ± 33.11 –5.99 ± 37.01 −3.47 ± 43.30 −13.57 ± 10.37
IL-10 (pg/mL)
 Pre-HD 227.25 ± 267.68 171.03 ± 181.34 452.15 ± 536.89 259.64 ± 341.91 285.86 ± 373.37 141.65 ± 140.36
 Post-HD 230.56 ± 272.62 169.59 ± 166.87 474.44 ± 570.34 275.46 ± 299.78 306.26 ± 323.69 136.86 ± 116.16
 Difference 3.31 ± 24.52 −1.43 ± 22.02 22.28 ± 33.45 15.82 ± 63.87 20.40 ± 69.98 −4.79 ± 24.20
hs-CRP (mg/dL)
 Pre-HD 0.61 ± 0.78 0.77 ± 0.86 0.16 ± 0.10 0.83 ± 2.01 0.89 ± 2.33 0.69 ± 0.77
 Post-HD 0.52 ± 0.62 0.74 ± 0.86 0.19 ± 0.13 0.54 ± 0.93 0.49 ± 0.95 0.67 ± 0.94
 Difference −0.09 ± 0.53 −0.13 ± 0.62 0.03 ± 0.03 −0.29 ± 1.52 −0.40 ± 1.78 −0.02 ± 0.30
tHcy (μmol/L)
 Pre-HD 22.14 ± 3.29 21.84 ± 7.02 20.82 ± 0.23 18.88 ± 4.31 17.82 ± 5.42 20.10 ± 2.41
 Post-HD 9.91 ± 4.59† 10.68 ± 4.06† 6.42 ± 4.92† 6.22 ± 4.61† 9.97 ± 2.48† 1.85 ± 0.91†‡§
 Difference −12.23 ± 6.16 −11.75 ± 6.37 −14.38 ± 6.64 −12.65 ± 6.35 −7.85 ± 4.33 −18.25 ± 2.13¶
*Data presented as mean ± standard deviation; †p < 0.05 considered statistically significant before and after HD for within-group differences by 
Mann-Whitney U test (NS group, p < 0.001; NS with anuria subgroup, p = 0.001; NS with residual renal function subgroup, p = 0.034; NAC group, 
p < 0.001; NAC with anuria subgroup, p = 0.003; NAC with residual renal function subgroup, p < 0.001); ‡p < 0.05 considered statistically signifi-
cant for NS group compared with NAC with residual renal function subgroup by Mann-Whitney U test (p = 0.002); §p < 0.05 considered statistically 
significant for NS with anuria subgroup compared with NAC with residual renal function subgroup by Mann-Whitney U test (p < 0.001); p < 0.05 
considered statistically significant for NAC with anuria subgroup compared with NAC with residual renal function subgroup by Mann-Whitney 
U test (p = 0.001); ¶p < 0.05 considered statistically significant for NAC with anuria subgroup compared with NAC with residual renal function 
subgroup by Mann-Whitney U test (p = 0.001). TNF-α = tumor necrosis factor-α; HD = hemodialysis; IL-10 = interleukin-10; hs-CRP = high-sensitivity 
C-reactive protein; tHcy = total homocysteine.
 TZU CHI MED J  June 2010  Vol 22  No 2 95
patients with end-stage renal disease? Am J Med 2001;
110:198–204.
4. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple 
JD. Malnutrition-inflammation complex syndrome in dialy-
sis patients: causes and consequences. Am J Kidney Dis 
2003;42:864–81.
5. Arici M, Walls J. End-stage renal disease, atherosclerosis, and 
cardiovascular mortality: is C-reactive protein the missing 
link? Kidney Int 2001;59:407–14.
6. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and 
TNF-alpha: central factors in the altered cytokine network 
of uremia—the good, the bad, and the ugly. Kidney Int 
2005;67:1216–33.
7. Rubin C, Nolin TD, Himmelfarb J. Are biomarkers useful for 
assessing cardiovascular risk in patients with chronic kidney 
disease? Curr Opin Nephrol Hypertens 2007;16:506–11.
8. Hsu BG, Yang FL, Lee RP, Peng TC, Harn HJ, Chen HI. 
N-acetylcysteine ameliorates lipopolysaccharide-induced 
organ damage in conscious rats. J Biomed Sci 2004;11:
152–62.
9. Hsu BG, Lee RP, Yang FL, Harn HJ, Chen HI. Post-treatment 
with N-acetylcysteine ameliorates the endotoxin shock-
induced organ damage in conscious rats. Life Sci 2006;79:
2010–6.
10. Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G. 
N-acetylcysteine reduces homocysteine plasma levels after 
single intravenous administration by increasing thiols uri-
nary excretion. Pharmacol Res 1999;40:345–50.
11. Wang JH, Subeq YM, Tsai WC, Lee RP, Hsu BG. Intravenous 
N-acetylcysteine improves renal function and ameliorates 
plasma total homocysteine in patients undergoing cardiac 
angiography. Ren Fail 2008;30:527–33.
12. Thaha M, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine 
during haemodialysis reduces the plasma concentration 
of homocysteine in patients with end-stage renal disease. 
Clin Drug Investig 2006;26:195–202.
13. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. 
Acetylcysteine reduces plasma homocysteine concentra-
tion and improves pulse pressure and endothelial func-
tion in patients with end-stage renal failure. Circulation 
2004;109:369–74.
14. Lee CC, Lee RP, Subeq YM, Wang CH, Fang TC, Hsu BG. Fasting 
serum total ghrelin level inversely correlates with metabolic 
syndrome in hemodialysis patients. Arch Med Res 2008;
39:785–90.
15. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The ele-
phant in uremia: oxidant stress as a unifying concept of 
cardiovascular disease in uremia. Kidney Int 2002;62:
1524–38.
16. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr 
Opin Nephrol Hypertens 2003;12:593–8.
17. Witko-Sarsat V, Gausson V, Nguyen AT, et al. AOPP-induced 
activation of human neutrophil and monocyte oxidative 
metabolism: a potential target for N-acetylcysteine treat-
ment in dialysis patients. Kidney Int 2003;64:82–91.
18. Perna AF, Acanfora F, Satta E, Lombardi C, Ingrosso D, De 
Santo NG. Hyperhomocysteinemia and cardiovascular 
disease in uremia: the newest evidence in epidemiology 
and mechanisms of action. Semin Nephrol 2004;24:
426–30.
19. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteine-
mia predicts cardiovascular outcomes in hemodialysis 
patients. Kidney Int 2002;61:609–14.
20. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. 
Impact of malnutrition-inflammation on the association 
between homocysteine and mortality. Kidney Int 2006;
69:331–5.
21. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homo-
cysteine lowering on mortality and vascular disease in 
advanced chronic kidney disease and end-stage renal 
disease: a randomized controlled trial. JAMA 2007;298:
1163–70.
22. Perna AF, Luciano MG, Pulzella P, et al. Is homocysteine 
toxic in uremia? J Ren Nutr 2008;18:12–7.
23. Friedman AN, Bostom AG, Laliberty P, Selhub J, Shemin D. 
The effect of N-acetylcysteine on plasma total homocysteine 
levels in hemodialysis: a randomized, controlled study. 
Am J Kidney Dis 2003;41:442–6.
24. Ventura P, Panini R, Abbati G, Marchetti G, Salvioli G. Urinary 
and plasma homocysteine and cysteine levels during pro-
longed oral N-acetylcysteine therapy. Pharmacology 2003;
68:105–14.
25. De Vriese AS, Langlois M, Bernard D, et al. Effect of dia-
lyser membrane pore size on plasma homocysteine levels 
in haemodialysis patients. Nephrol Dial Transplant 2003;
18:2596–600.
